Cytek Biosciences (CTKB) financial statements
Cytek Biosciences reported revenue of $201M in fiscal 2025, up 16.8% a year over 5 years.
Net income was -$67M and the operating margin -20.0%, against 14.7% in 2020.
Free cash flow was -$9M, and the company returned $15M in net buybacks.
The diluted share count rose 292% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Cytek Biosciences's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $93M | $128M | $164M | $193M | $200M | $201M |
| Cost of revenue | $41M | $49M | $63M | $84M | $89M | $97M |
| Gross profit | $52M | $79M | $101M | $109M | $111M | $104M |
| Research and development | $14M | $24M | $35M | $44M | $39M | $36M |
| Selling, general and admin | $24M | $46M | $68M | $93M | $92M | $108M |
| Operating income | $14M | $9M | -$2M | -$28M | -$21M | -$40M |
| Interest expense | $333,000 | $2M | $3M | $2M | -$5M | $474,000 |
| Pre-tax income | $14M | $6M | $1M | -$16M | -$6M | -$30M |
| Income tax | -$5M | $3M | -$1M | -$4M | $320,000 | $37M |
| Net income | $19M | $3M | $2M | -$12M | -$6M | -$67M |
| EPS (diluted) | $0.10 | $0.00 | $0.02 | -$0.09 | — | — |
| Diluted shares | 33M | 82M | 139M | 135M | 131M | 128M |
| Gross margin | 55.7% | 61.9% | 61.6% | 56.7% | 55.4% | 51.8% |
| Operating margin | 14.7% | 7.2% | -1.1% | -14.4% | -10.2% | -20.0% |
| Net margin | 20.9% | 2.4% | 1.5% | -6.3% | -3.0% | -33.0% |
Balance sheet
Fiscal years, from Cytek Biosciences's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $165M | $365M | $297M | $167M | $99M | $91M |
| Receivables | $17M | $30M | $49M | $56M | $61M | $63M |
| Inventory | $23M | $32M | $48M | $61M | $44M | $48M |
| Total current assets | $209M | $432M | $454M | $392M | $396M | $392M |
| Property, plant and equipment | $2M | $6M | $14M | $18M | $18M | $18M |
| Goodwill | $476,000 | $10M | $10M | $16M | $17M | $17M |
| Total assets | $220M | $463M | $519M | $494M | $500M | $462M |
| Total current liabilities | $27M | $33M | $49M | $56M | $68M | $78M |
| Total liabilities | $42M | $58M | $94M | $101M | $104M | $120M |
| Shareholders' equity | -$16M | $405M | $426M | $393M | $396M | $342M |
| Net debt | -$165M | -$365M | -$297M | -$167M | -$99M | -$91M |
Cash flow
Fiscal years, from Cytek Biosciences's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $15M | $5M | -$12M | $5M | $25M | -$5M |
| Capital spending | $2M | $4M | $10M | $5M | $4M | $4M |
| Free cash flow | $14M | $266,000 | -$22M | $633,000 | $22M | -$9M |
| Stock-based compensation | $611,000 | $7M | $17M | $22M | $27M | $25M |
| Share buybacks (net) | — | $0 | $0 | -$44M | -$22M | -$15M |
| Net borrowing | $0 | $0 | $3M | -$565,000 | -$557,000 | -$5M |
| Free cash flow margin | 14.7% | 0.2% | -13.4% | 0.3% | 10.9% | -4.4% |
Questions
What was Cytek Biosciences's revenue in 2025?
$201M in fiscal 2025, from its 10-K filing.
How much free cash flow does Cytek Biosciences generate?
-$9M in fiscal 2025 (operating cash flow minus capital spending).
From Cytek Biosciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.